---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-014267"
form_type: "8-K"
ticker: "SNGX"
cik: "0000812796"
company_name: "SOLIGENIX, INC."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:10:02.200719+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Soligenix provides pipeline update; FLASH 2 interim analysis in 2Q, cash through 2026

## Summary
- 66 patients enrolled in confirmatory Phase 3 FLASH 2 trial for HyBryte in CTCL as of Feb 10; interim analysis expected 2Q 2026.
- Blinded aggregate response rate in FLASH 2 remains higher than estimated rate used to design study, increasing confidence.
- Investigator-initiated study: 75% of patients achieved treatment success, 3 complete responses with HyBryte at 18 weeks.
- Cash ~$10.5M as of Sep 30, 2025, plus ~$500k from NJ NOL program; runway through 2026.
- Positive Phase 2a results for SGX945 (Behçet’s) and SGX302 (psoriasis); Phase 2b design underway in 2026.

## SEC filing metadata
- accession: 0001104659-26-014267
- form_type: 8-K
- ticker: SNGX
- cik: 0000812796
- company_name: SOLIGENIX, INC.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/812796/000110465926014267/0001104659-26-014267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/812796/000110465926014267/sngx-20260212x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-014267
- JSON: https://secwatch.observer/filing/0001104659-26-014267.json
- Plain text: https://secwatch.observer/filing/0001104659-26-014267.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.